AU2021388076B2 - Compositions comprising flumazenil and naltrexone and methods for use thereof - Google Patents

Compositions comprising flumazenil and naltrexone and methods for use thereof

Info

Publication number
AU2021388076B2
AU2021388076B2 AU2021388076A AU2021388076A AU2021388076B2 AU 2021388076 B2 AU2021388076 B2 AU 2021388076B2 AU 2021388076 A AU2021388076 A AU 2021388076A AU 2021388076 A AU2021388076 A AU 2021388076A AU 2021388076 B2 AU2021388076 B2 AU 2021388076B2
Authority
AU
Australia
Prior art keywords
naltrexone
flumazenil
micrograms
administered
ranging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021388076A
Other languages
English (en)
Other versions
AU2021388076A1 (en
AU2021388076A9 (en
Inventor
Julian CHICK
Lee Eric RODNE
Daniel John ZANARDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trexapharm Pty Ltd
Original Assignee
Trexapharm Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904390A external-priority patent/AU2020904390A0/en
Application filed by Trexapharm Pty Ltd filed Critical Trexapharm Pty Ltd
Publication of AU2021388076A1 publication Critical patent/AU2021388076A1/en
Publication of AU2021388076A9 publication Critical patent/AU2021388076A9/en
Application granted granted Critical
Publication of AU2021388076B2 publication Critical patent/AU2021388076B2/en
Priority to AU2025267401A priority Critical patent/AU2025267401A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021388076A 2020-11-27 2021-11-26 Compositions comprising flumazenil and naltrexone and methods for use thereof Active AU2021388076B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025267401A AU2025267401A1 (en) 2020-11-27 2025-11-13 Compositions comprising flumazenil and naltrexone and methods for use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020904390 2020-11-27
AU2020904390A AU2020904390A0 (en) 2020-11-27 Compositions and methods
PCT/AU2021/051413 WO2022109677A1 (en) 2020-11-27 2021-11-26 Compositions comprising flumazenil and naltrexone and methods for use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025267401A Division AU2025267401A1 (en) 2020-11-27 2025-11-13 Compositions comprising flumazenil and naltrexone and methods for use thereof

Publications (3)

Publication Number Publication Date
AU2021388076A1 AU2021388076A1 (en) 2023-06-15
AU2021388076A9 AU2021388076A9 (en) 2024-08-08
AU2021388076B2 true AU2021388076B2 (en) 2025-08-14

Family

ID=81753640

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021388076A Active AU2021388076B2 (en) 2020-11-27 2021-11-26 Compositions comprising flumazenil and naltrexone and methods for use thereof
AU2025267401A Pending AU2025267401A1 (en) 2020-11-27 2025-11-13 Compositions comprising flumazenil and naltrexone and methods for use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025267401A Pending AU2025267401A1 (en) 2020-11-27 2025-11-13 Compositions comprising flumazenil and naltrexone and methods for use thereof

Country Status (9)

Country Link
US (4) US12521401B2 (enExample)
EP (1) EP4251168A4 (enExample)
JP (1) JP2024501919A (enExample)
KR (1) KR20230110793A9 (enExample)
CN (2) CN121695144A (enExample)
AU (2) AU2021388076B2 (enExample)
CA (1) CA3201498A1 (enExample)
IL (1) IL303117A (enExample)
WO (1) WO2022109677A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106574A1 (en) * 2023-11-14 2025-05-22 Aardwolf Therapeutics, Inc. Flumazenil for treating post-traumatic stress disorder and anxiety
USD1127473S1 (en) * 2023-12-28 2026-05-26 Ceragem Co., Ltd. Easy chair
JP1807091S (ja) * 2023-12-28 2025-08-26 安楽椅子
JP1807096S (ja) * 2023-12-28 2025-08-26 安楽椅子

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160256472A1 (en) * 2013-10-14 2016-09-08 Palmaya Pty Ltd Compositions and methods of administering same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
ES2289935B1 (es) 2006-07-14 2008-12-16 Juan Jose Legarda Ibañez Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva.
WO2010094074A1 (en) * 2009-02-20 2010-08-26 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
US20150111916A9 (en) * 2010-04-29 2015-04-23 Annette Channa Toledano Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
CA2899455C (en) * 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
WO2014186824A1 (en) * 2013-05-20 2014-11-27 Palmaya Pty Ltd Treatment of neurological and other disorders
US20220152044A1 (en) * 2019-03-14 2022-05-19 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160256472A1 (en) * 2013-10-14 2016-09-08 Palmaya Pty Ltd Compositions and methods of administering same

Also Published As

Publication number Publication date
US12521401B2 (en) 2026-01-13
EP4251168A4 (en) 2024-11-06
WO2022109677A1 (en) 2022-06-02
CN121695144A (zh) 2026-03-20
IL303117A (en) 2023-07-01
US20240000796A1 (en) 2024-01-04
CN116648246A (zh) 2023-08-25
JP2024501919A (ja) 2024-01-17
US20260102405A1 (en) 2026-04-16
KR20230110793A (ko) 2023-07-25
KR20230110793A9 (ko) 2024-11-13
CA3201498A1 (en) 2022-06-02
US20260166054A1 (en) 2026-06-18
AU2021388076A1 (en) 2023-06-15
US20260166053A1 (en) 2026-06-18
AU2021388076A9 (en) 2024-08-08
EP4251168A1 (en) 2023-10-04
AU2025267401A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
US12521401B2 (en) Compositions comprising flumazenil and naltrexone and methods for use thereof
US12453726B2 (en) Methods of using factor B inhibitors
RU2746000C2 (ru) Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US6492333B1 (en) Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
RU2769397C2 (ru) Композиции и способы лечения передозировки опиоидами
CN102133171A (zh) 延缓释放阿立哌唑的可注射组合物
EP2827858B1 (en) Administration of an antitumor agent
EP1896025B1 (en) Scopolamine for the treatment of depression and anxiety
RU2268725C2 (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
US9700565B2 (en) Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
US20050255096A1 (en) Combination treatment for acute myocardial infarction
US20170065579A1 (en) Sustained Release Low Dose Formulations and Uses Thereof
US20050197286A1 (en) Method for control of depression using c terminal growth hormone (gh) fragment
US20110301102A1 (en) Compositions and methods for treating myelodysplastic syndrome
JP6702883B2 (ja) 向神経活性ペプチドの安定な組成物
JP2023548525A (ja) カフェイン組成物
EP4364742A1 (en) Pharmaceutical composition for treating solid tumors
EP0254313B1 (en) Use of ketamine for the manufacturing of medicaments for prevention or reduction of the effects of stroke in a subject having increased risk for stroke
US11547685B2 (en) Using probenecid to treat polycystic kidney disease
CN118829427A (zh) 治疗腹型肥胖、高甘油三酯血症和/或血糖受损受试者的方法
Lucas et al. Shaking, chills, and rigors with once‐daily gentamicin
AU2006246490B2 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
AU2022201576A1 (en) Medication
CN116456998A (zh) 咖啡因组合物
TW202604485A (zh) 患有肝損傷患者肝疾病之治療

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)